Siren L.L.C. Increases Stock Holdings in Monopar Therapeutics Inc. $MNPR

Siren L.L.C. raised its position in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) by 27.2% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 270,118 shares of the company’s stock after purchasing an additional 57,820 shares during the quarter. Siren L.L.C.’s holdings in Monopar Therapeutics were worth $14,800,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Janus Henderson Group PLC lifted its stake in shares of Monopar Therapeutics by 2.3% in the 4th quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company’s stock worth $85,908,000 after purchasing an additional 30,042 shares during the period. RA Capital Management L.P. grew its position in Monopar Therapeutics by 30.5% during the fourth quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock valued at $43,569,000 after buying an additional 156,000 shares during the period. ADAR1 Capital Management LLC grew its position in Monopar Therapeutics by 79.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 233,908 shares of the company’s stock valued at $15,274,000 after buying an additional 103,909 shares during the period. Wellington Management Group LLP bought a new stake in Monopar Therapeutics during the third quarter valued at approximately $18,904,000. Finally, Vanguard Group Inc. increased its holdings in Monopar Therapeutics by 140.7% during the third quarter. Vanguard Group Inc. now owns 208,218 shares of the company’s stock valued at $17,005,000 after buying an additional 121,729 shares during the last quarter. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Price Performance

Shares of NASDAQ:MNPR opened at $105.70 on Friday. Monopar Therapeutics Inc. has a 1-year low of $29.18 and a 1-year high of $116.64. The company has a market capitalization of $708.19 million, a P/E ratio of -55.63 and a beta of 1.46. The firm’s 50 day simple moving average is $79.49 and its two-hundred day simple moving average is $66.36.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.41. On average, sell-side analysts anticipate that Monopar Therapeutics Inc. will post -2.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on MNPR. UBS Group set a $125.00 price target on shares of Monopar Therapeutics in a research note on Thursday. Piper Sandler set a $105.00 price objective on Monopar Therapeutics in a research note on Tuesday, June 2nd. HC Wainwright raised their target price on Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday. BTIG Research lifted their target price on Monopar Therapeutics from $104.00 to $117.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Finally, Zacks Research raised Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. Three investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $112.08.

Monopar Therapeutics Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.